RU2005113999A - Твердый препарат - Google Patents
Твердый препарат Download PDFInfo
- Publication number
- RU2005113999A RU2005113999A RU2005113999/15A RU2005113999A RU2005113999A RU 2005113999 A RU2005113999 A RU 2005113999A RU 2005113999/15 A RU2005113999/15 A RU 2005113999/15A RU 2005113999 A RU2005113999 A RU 2005113999A RU 2005113999 A RU2005113999 A RU 2005113999A
- Authority
- RU
- Russia
- Prior art keywords
- solid preparation
- active ingredient
- biguanide
- insulin
- phase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Твердый препарат, имеющий фазу, в которой однородно диспергированы сенсибилизатор инсулина и активный ингредиент, за исключением сенсибилизаторов инсулина, и характеризующийся твердостью, равной 100-400 Н.
2. Твердый препарат по п.1, в котором активный ингредиент является бигуанидом.
3. Твердый препарат по п.2, в котором бигуанид является гидрохлоридом метформина.
4. Твердый препарат, имеющий фазу, в которой однородно диспергированы сенсибилизатор инсулина и активный ингредиент, за исключением сенсибилизаторов инсулина, и характеризующийся соотношением среднего размера частиц активного ингредиента и сенсибилизатора инсулина, равным 0,5:15.
5. Твердый препарат по п.4, в котором активный ингредиент является бигуанидом.
6. Твердый препарат по п.5, в котором бигуанид является гидрохлоридом метформина.
7. Твердый препарат, имеющий фазу, в которой однородно диспергированы сенсибилизатор инсулина и активный ингредиент, за исключением сенсибилизаторов инсулина, и характеризующийся коэффициентом вариации содержания сенсибилизатора инсулина, не превышающим 6%.
8. Твердый препарат по п.7, в котором активный ингредиент является бигуанидом.
9. Твердый препарат по п.8, в котором бигуанид является гидрохлоридом метформина.
10. Твердый препарат, имеющий фазу, в которой однородно диспергированы сенсибилизатор инсулина и активный ингредиент, за иключением сенсибилизаторов инсулина, и характеризующийся элюированием не менее 70% сенсибилизатора инсулина через 30 мин при выполнении испытания на растворимость лопастным методом при 37°С со скоростью вращения 50 об/мин с использованием буфера, содержащего хлористоводородную кислоту и хлорид калия при рН 2,0, в качестве испытуемого раствора.
11. Твердый препарат по п.10, в котором активный ингредиент является бигуанидом.
12. Твердый препарат по п.11, в котором бигуанид является гидрохлоридом метформина.
13. Твердый препарат, имеющий фазу, в которой однородно диспергированы гидрохлорид пиоглитазона и гидрохлорид метформина, и характеризующийся соотношением среднего размера частиц гидрохлорида метформина и гидрохлорида пиоглитазона, равным 0,5:15.
14. Твердый препарат по п.13, который имеет пленочное покрытие.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-294045 | 2002-10-07 | ||
| JP2002294045 | 2002-10-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005113999A true RU2005113999A (ru) | 2005-12-10 |
| RU2357757C2 RU2357757C2 (ru) | 2009-06-10 |
Family
ID=32064024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005113999/15A RU2357757C2 (ru) | 2002-10-07 | 2003-10-06 | Твердый препарат |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9101660B2 (ru) |
| EP (1) | EP1561472B2 (ru) |
| JP (2) | JP4236553B2 (ru) |
| KR (2) | KR20070119095A (ru) |
| CN (1) | CN100427143C (ru) |
| AU (1) | AU2003271103B2 (ru) |
| BR (1) | BR0315082A (ru) |
| CA (1) | CA2501587C (ru) |
| CO (1) | CO5700740A2 (ru) |
| CR (1) | CR7797A (ru) |
| CY (1) | CY1114863T1 (ru) |
| DK (1) | DK1561472T3 (ru) |
| ES (1) | ES2437072T5 (ru) |
| HK (1) | HK1080385A1 (ru) |
| IL (1) | IL167835A (ru) |
| MA (1) | MA27487A1 (ru) |
| MX (1) | MXPA05003668A (ru) |
| NO (1) | NO332993B1 (ru) |
| NZ (2) | NZ552559A (ru) |
| PL (1) | PL219608B1 (ru) |
| PT (1) | PT1561472E (ru) |
| RU (1) | RU2357757C2 (ru) |
| SI (1) | SI1561472T1 (ru) |
| UA (1) | UA80991C2 (ru) |
| WO (1) | WO2004030700A1 (ru) |
| ZA (1) | ZA200503507B (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1588708A4 (en) | 2003-01-29 | 2006-03-01 | Takeda Pharmaceutical | METHOD FOR PRODUCING COATED PREPARATION |
| US7198653B2 (en) | 2003-07-31 | 2007-04-03 | Delavau Llc | Calcium carbonate granulation |
| NZ546337A (en) | 2003-10-31 | 2009-03-31 | Takeda Pharmaceutical | Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80 |
| EP1738754B1 (en) | 2004-04-14 | 2015-07-15 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
| CA2607419C (en) * | 2005-04-26 | 2014-06-17 | Dainippon Sumitomo Pharma Co., Ltd. | Granular preparation containing biguanide compound |
| ES2576258T3 (es) * | 2005-12-22 | 2016-07-06 | Takeda Pharmaceutical Company Limited | Preparación sólida que contiene un sensibilizador de insulina |
| KR101220643B1 (ko) * | 2006-08-16 | 2013-01-14 | 알리코제약(주) | 사포그릴레이트 함유 경구투여 형태의 약제 |
| US9138414B1 (en) | 2006-09-15 | 2015-09-22 | Delavau Llc | Calcium supplement having enhanced absorption |
| JP4832271B2 (ja) * | 2006-12-11 | 2011-12-07 | 花王株式会社 | 粉末圧縮錠剤 |
| EP2185138B1 (en) | 2007-07-19 | 2016-09-07 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
| WO2009030257A1 (en) * | 2007-09-05 | 2009-03-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Methods and compounds for treating diseases caused by reactive oxygen species |
| CN101417130B (zh) * | 2007-10-22 | 2010-10-06 | 鲁南制药集团股份有限公司 | 一种治疗ⅱ型糖尿病及其并发症的药物组合物 |
| TR200803177A2 (tr) * | 2008-05-06 | 2009-11-23 | Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. | Antihiperglisemik etkili metformîn - pioglitazon formülasyonu. |
| WO2010084504A2 (en) * | 2008-05-26 | 2010-07-29 | Sun Pharmaceutical Industries Ltd. | A stable, oral solid dosage form |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| TW201138843A (en) | 2009-12-18 | 2011-11-16 | Colgate Palmolive Co | Biguanide preservation of precipitated calcium carbonate |
| ES2550033T3 (es) | 2009-12-23 | 2015-11-04 | Ratiopharm Gmbh | Forma de dosificación farmacéutica sólida de ticagrelor |
| WO2012012156A1 (en) * | 2010-07-21 | 2012-01-26 | Myomics, Inc. | Methods and compositions for the improvement of skeletal muscle function in a mammal |
| EP2441442A1 (en) * | 2010-10-08 | 2012-04-18 | LEK Pharmaceuticals d.d. | A pharmaceutical composition comprising a thiazolidinedione |
| TWI631963B (zh) * | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法 |
| RU2465896C2 (ru) * | 2011-01-20 | 2012-11-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая противодиабетическая композиция пролонгированного действия |
| CN105125539A (zh) * | 2015-08-05 | 2015-12-09 | 浙江华海药业股份有限公司 | 吡格列酮二甲双胍片及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69331839T2 (de) * | 1992-01-29 | 2002-12-12 | Takeda Chemical Industries, Ltd. | Schnellösliche Tablette und ihre Herstellung |
| TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| CN1222317C (zh) * | 1996-07-12 | 2005-10-12 | 第一制药株式会社 | 可迅速崩解的压模物质及其生产方法 |
| US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| US6291495B1 (en) | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
| WO1998057634A1 (en) | 1997-06-18 | 1998-12-23 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and metformin |
| GB9715295D0 (en) | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
| JPH1160476A (ja) | 1997-08-25 | 1999-03-02 | Taisho Pharmaceut Co Ltd | 圧縮固形組成物 |
| CN1203846C (zh) | 1998-03-19 | 2005-06-01 | 布里斯托尔-迈尔斯斯奎布公司 | 高溶解性药物的双相控释递送系统和方法 |
| EP1561458B1 (en) † | 1998-07-28 | 2010-09-15 | Takeda Pharmaceutical Company Limited | Rapidly disintegrable solid preparation |
| US6117451A (en) * | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
| AU768994B2 (en) † | 1998-11-12 | 2004-01-15 | Smithkline Beecham Plc | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| CA2354053A1 (en) | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes |
| EP1210087A2 (en) | 1999-04-29 | 2002-06-05 | City of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| CO5200844A1 (es) | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
| US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
| JP2003514011A (ja) * | 1999-11-16 | 2003-04-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物 |
| US6780432B1 (en) | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
| US6524621B2 (en) * | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
| US6403121B1 (en) * | 2000-05-01 | 2002-06-11 | Aeropharm Technology Incorporated | Core formulation |
| JP2001335469A (ja) | 2000-05-26 | 2001-12-04 | Lion Corp | 固体製剤の製造方法 |
| FR2812547B1 (fr) | 2000-08-04 | 2002-10-31 | Lipha | Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete |
| JP2002087965A (ja) * | 2000-09-14 | 2002-03-27 | Lion Corp | 口中崩壊性アスピリン含有錠剤 |
| WO2002030400A1 (fr) * | 2000-10-06 | 2002-04-18 | Takeda Chemical Industries, Ltd. | Preparations solides |
| JP4284017B2 (ja) * | 2000-10-06 | 2009-06-24 | 武田薬品工業株式会社 | 固形製剤 |
| UA80393C2 (ru) | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице |
| US20060286168A1 (en) | 2002-07-11 | 2006-12-21 | Masahiko Koike | Process for producing coated preparation |
-
2003
- 2003-06-10 UA UAA200504320A patent/UA80991C2/uk unknown
- 2003-10-06 WO PCT/JP2003/012781 patent/WO2004030700A1/ja not_active Application Discontinuation
- 2003-10-06 US US10/530,262 patent/US9101660B2/en active Active
- 2003-10-06 CN CNB2003801044191A patent/CN100427143C/zh not_active Expired - Lifetime
- 2003-10-06 CA CA002501587A patent/CA2501587C/en not_active Expired - Lifetime
- 2003-10-06 PL PL376176A patent/PL219608B1/pl unknown
- 2003-10-06 RU RU2005113999/15A patent/RU2357757C2/ru active
- 2003-10-06 ES ES03751344T patent/ES2437072T5/es not_active Expired - Lifetime
- 2003-10-06 BR BR0315082-8A patent/BR0315082A/pt not_active Application Discontinuation
- 2003-10-06 SI SI200332322T patent/SI1561472T1/sl unknown
- 2003-10-06 NZ NZ552559A patent/NZ552559A/en not_active IP Right Cessation
- 2003-10-06 MX MXPA05003668A patent/MXPA05003668A/es active IP Right Grant
- 2003-10-06 JP JP2003346699A patent/JP4236553B2/ja not_active Expired - Lifetime
- 2003-10-06 KR KR1020077027585A patent/KR20070119095A/ko not_active Application Discontinuation
- 2003-10-06 EP EP03751344.7A patent/EP1561472B2/en not_active Expired - Lifetime
- 2003-10-06 DK DK03751344.7T patent/DK1561472T3/da active
- 2003-10-06 KR KR1020057006007A patent/KR100820609B1/ko active IP Right Grant
- 2003-10-06 AU AU2003271103A patent/AU2003271103B2/en not_active Expired
- 2003-10-06 PT PT37513447T patent/PT1561472E/pt unknown
- 2003-10-06 NZ NZ539711A patent/NZ539711A/en not_active IP Right Cessation
-
2005
- 2005-04-03 IL IL167835A patent/IL167835A/en unknown
- 2005-04-19 CR CR7797A patent/CR7797A/es unknown
- 2005-05-03 ZA ZA200503507A patent/ZA200503507B/en unknown
- 2005-05-04 MA MA28258A patent/MA27487A1/fr unknown
- 2005-05-05 CO CO05043503A patent/CO5700740A2/es not_active Application Discontinuation
- 2005-05-06 NO NO20052239A patent/NO332993B1/no not_active IP Right Cessation
-
2006
- 2006-01-12 HK HK06100508.9A patent/HK1080385A1/xx not_active IP Right Cessation
-
2008
- 2008-05-12 JP JP2008125325A patent/JP2008208141A/ja active Pending
-
2013
- 2013-12-09 CY CY20131101109T patent/CY1114863T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005113999A (ru) | Твердый препарат | |
| JP2004149521A5 (ru) | ||
| JP2006502187A5 (ru) | ||
| JP2005532990A5 (ru) | ||
| BRPI0513904A (pt) | forma farmacêutica de multipartìcula para substáncias ativas de baixa solubilidade e um processo para preparar a forma farmacêutica | |
| RU2005122008A (ru) | Препараты с контролируемым высвобождением, содержащие трамадол и топирамат | |
| JP2012512907A5 (ru) | ||
| NO20062082L (no) | Pellets inneholdende venlafaksinhydroklorid | |
| WO2004060352A1 (en) | Non-hygroscopic formulation comprising a hydroscopic drug | |
| JP2010525033A5 (ru) | ||
| NO20073928L (no) | Stabilt partikkelformig legemiddel med solifenacin eller salt av dette | |
| RU2005127081A (ru) | Способ получения препарата с покрытием | |
| JP2011502997A5 (ru) | ||
| RU2002106399A (ru) | Составы моксифлоксацина, содержащие поваренную соль | |
| RU2007128342A (ru) | Твердый препарат, содержащий восстановленный кофермент q10 и способ его продуцирования | |
| CA2540225A1 (en) | Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester | |
| JP2001513506A5 (ru) | ||
| JP2006335648A5 (ru) | ||
| JP2004534073A5 (ru) | ||
| JP2011503142A5 (ru) | ||
| CA2155520A1 (en) | Starch hydrolysates as sequesterers | |
| BR0305070A (pt) | Uso de derivado amida de ge 2270 fator a3 para tratamento da acne | |
| JP2004067575A (ja) | 糖尿病治療薬効果促進剤 | |
| JP6766044B2 (ja) | 継粉形成抑制剤 | |
| RU2009139917A (ru) | Фармацевтическая композиция |